home / case-based-peer-perspectives / first-line-treatment-for-egfr-mutated-advanced-metastatic-non-small-cell-lung-cancer-a-47-year ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Rezivertinib outperforms gefitinib as first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Ann Oncol.

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...